Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

Cancer Cell

Volumn 31, Issue 2, 2017, Pages 286-299

  Gardner, Eric E ^a,b   Lok, Benjamin H ^b   Schneeberger, Valentina E ^b   Desmeules, Patrice ^b   Miles, Linde A ^b   Arnold, Paige K ^b   Ni, Andy ^b   Khodos, Inna ^b   de Stanchina, Elisa ^b   Nguyen, Thuyen ^c   Sage, Julien ^c   Campbell, John E ^d   Ribich, Scott ^d   Rekhtman, Natasha ^b   Dowlati, Afshin ^e   Massion, Pierre P ^f   Rudin, Charles M ^b,g   Poirier, John T ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d EPIZYME INC   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

acquired resistance; cisplatin; EPZ011989; etoposide; EZH2; patient derived xenograft; SLFN11; small cell lung cancer; TWIST1

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BETA SECRETASE 2; BEX5 PROTEIN; CISPLATIN; COL22A1 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA HELICASE; EPZ 011989; ETOPOSIDE; HISTONE LYSINE METHYLTRANSFERASE; IRINOTECAN; MESSENGER RNA; NOTCH1 RECEPTOR; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INHIBITOR; PROTEIN P130; PROTEIN P53; RB1 PROTEIN; RNA HELICASE; SCHLAFEN 11 PROTEIN; SHORT HAIRPIN RNA; SPNS2 PROTEIN; TOPOTECAN; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; TUMOR PROTEIN P73; TWIST RELATED PROTEIN 1; UNCLASSIFIED DRUG; UVOMORULIN; EZH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; SLFN11 PROTEIN, HUMAN; TWIST1 PROTEIN, HUMAN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CHEMOSENSITIVITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GENE SILENCING; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MAINTENANCE CHEMOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PHYSIOLOGY; SMALL CELL LUNG CARCINOMA;

ANIMALS; DRUG RESISTANCE, NEOPLASM; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HUMANS; LUNG NEOPLASMS; MICE; NUCLEAR PROTEINS; SMALL CELL LUNG CARCINOMA; TWIST-RELATED PROTEIN 1;

EID: 85012931265     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.01.006     Document Type: Article

References (45)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
3. Beck, B., Lapouge, G., Rorive, S., Drogat, B., Desaedelaere, K., Delafaille, S., Dubois, C., Salmon, I., Willekens, K., Marine, J.C., Blanpain, C., Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 16 (2015), 67–79.
4. Belani, C.P., Dahlberg, S.E., Rudin, C.M., Fleisher, M., Chen, H.X., Takebe, N., Velasco, M.R. Jr., Tester, W.J., Sturtz, K., Hann, C.L., et al. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122 (2016), 2371–2378.
5. Carney, D.N., Gazdar, A.F., Bepler, G., Guccion, J.G., Marangos, P.J., Moody, T.W., Zweig, M.H., Minna, J.D., Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45 (1985), 2913–2923.
6. Christensen, C.L., Kwiatkowski, N., Abraham, B.J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G.S., Akbay, E.A., Altabef, A., et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26 (2014), 909–922.
7. Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L., Rudin, C.M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C.D., Watkins, D.N., A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69 (2009), 3364–3373.
8. De Smet, C., Lurquin, C., Lethe, B., Martelange, V., Boon, T., DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell Biol. 19 (1999), 7327–7335.
9. Fillmore, C.M., Xu, C., Desai, P.T., Berry, J.M., Rowbotham, S.P., Lin, Y.J., Zhang, H., Marquez, V.E., Hammerman, P.S., Wong, K.K., Kim, C.F., EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520 (2015), 239–242.
10. Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
11. George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretic, L., Kong, G., Leenders, F., Lu, X., Fernandez-Cuesta, L., Bosco, G., et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015), 47–53.
12. Gerstein, M.B., Kundaje, A., Hariharan, M., Landt, S.G., Yan, K.K., Cheng, C., Mu, X.J., Khurana, E., Rozowsky, J., Alexander, R., et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489 (2012), 91–100.
13. Horita, N., Yamamoto, M., Sato, T., Tsukahara, T., Nagakura, H., Tashiro, K., Shibata, Y., Watanabe, H., Nagai, K., Inoue, M., et al. Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients. Sci. Rep., 5, 2015, 15437.
14. Jadhav, U., Nalapareddy, K., Saxena, M., O'Neill, N.K., Pinello, L., Yuan, G.C., Orkin, S.H., Shivdasani, R.A., Acquired tissue-specific promoter bivalency is a basis for PRC2 necessity in adult cells. Cell 165 (2016), 1389–1400.
15. Kalemkerian, G.P., Akerley, W., Bogner, P., Borghaei, H., Chow, L.Q., Downey, R.J., Gandhi, L., Ganti, A.K., Govindan, R., Grecula, J.C., et al. Small cell lung cancer. J. Natl. Compr. Canc. Netw. 11 (2013), 78–98.
16. LaFave, L.M., Beguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M.D., Hricik, T., Konstantinoff, K., et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21 (2015), 1344–1349.
17. Lin, C.Y., Loven, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I., Young, R.A., Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151 (2012), 56–67.
18. Lok, B.H., Gardner, E.E., Schneeberger, V.E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B.A., Riaz, N., Powell, S.N., et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with Temozolomide in small cell lung cancer. Clin. Cancer Res. 23 (2016), 523–535.
19. Loven, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R., Bradner, J.E., Lee, T.I., Young, R.A., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 (2013), 320–334.
20. Maia, A.M., da Silva, J.H., Mencalha, A.L., Caffarena, E.R., Abdelhay, E., Computational modeling of the bHLH domain of the transcription factor TWIST1 and R118C, S144R and K145E mutants. BMC Bioinformatics, 13, 2012, 184.
21. McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Graves, A.P., Della Pietra, A. 3rd, Diaz, E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492 (2012), 108–112.
22. Morschhauser, F., Salles, G., McKay, P., Le Gouill, S., Tilly, H., Radford, J.A., Cartron, G., Dickinson, M.J., Fruchart, C., Gribben, J.G., et al. Initial report from a phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of Zeste-Homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Presented at the 2016 ASH Meeting on Lymphoma Biology, June 20, 2016; Colorado Springs, CO.
23. Mu, Y., Lou, J., Srivastava, M., Zhao, B., Feng, X.H., Liu, T., Chen, J., Huang, J., SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep. 17 (2016), 94–109.
24. Nogales, V., Reinhold, W.C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., Esteller, M., Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 7 (2016), 3084–3097.
25. Park, K.S., Martelotto, L.G., Peifer, M., Sos, M.L., Karnezis, A.N., Mahjoub, M.R., Bernard, K., Conklin, J.F., Szczepny, A., Yuan, J., et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med. 17 (2011), 1504–1508.
26. Poirier, J.T., Gardner, E.E., Connis, N., Moreira, A.L., de Stanchina, E., Hann, C.L., Rudin, C.M., DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 34 (2015), 5869–5878.
27. Polley, E., Kunkel, M., Evans, D., Silvers, T., Delosh, R., Laudeman, J., Ogle, C., Reinhart, R., Selby, M., Connelly, J., et al. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. J. Natl. Cancer Inst., 108, 2016, 10.1093/jnci/djw122.
28. Pott, S., Lieb, J.D., What are super-enhancers?. Nat. Genet. 47 (2015), 8–12.
29. Ribrag, V., Soria, J.-C., Michot, J.-M., Schmitt, A., Postel-Vinay, S., Bijou, F., Coindre, J.-M., Toulemonde, M., Blakemore, S.J., Suttle, B., et al. A phase 1 study of tazemetostat (EPZ-6438), an inhibitor of EZH2: preliminary safety and activity in patients with relapsed or refractory NHL and advanced solid tumors. Presented at the 2016 ASH Meeting on Lymphoma Biology, June 21, 2016; Colorado Springs, CO.
30. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., Swanton, C., DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol., 17, 2016, 31.
31. Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, E.A., Guan, Y., Shin, J., Guillory, J., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44 (2012), 1111–1116.
32. Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Marquez, V.E., et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci. Rep., 3, 2013, 1911.
33. Schmidt, J.M., Panzilius, E., Bartsch, H.S., Irmler, M., Beckers, J., Kari, V., Linnemann, J.R., Dragoi, D., Hirschi, B., Kloos, U.J., et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 10 (2015), 131–139.
34. Schneeberger, V.E., Allaj, V., Gardner, E.E., Poirier, J.T., Rudin, C.M., Quantitation of murine stroma and selective purification of the human tumor component of patient-derived xenografts for genomic analysis. PLoS One, 11, 2016, e0160587.
35. Shepherd, F.A., Crowley, J., Van Houtte, P., Postmus, P.E., Carney, D., Chansky, K., Shaikh, Z., Goldstraw, P., International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions, The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J. Thorac. Oncol. 2 (2007), 1067–1077.
36. Sousa, F.G., Matuo, R., Tang, S.W., Rajapakse, V.N., Luna, A., Sander, C., Varma, S., Simon, P.H., Doroshow, J.H., Reinhold, W.C., Pommier, Y., Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst) 28 (2015), 107–115.
37. Stewart, E., Goshorn, R., Bradley, C., Griffiths, L.M., Benavente, C., Twarog, N.R., Miller, G.M., Caufield, W., Freeman, B.B. 3rd, Bahrami, A., et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 9 (2014), 829–841.
38. Tang, S.W., Bilke, S., Cao, L., Murai, J., Sousa, F.G., Yamade, M., Rajapakse, V., Varma, S., Helman, L.J., Khan, J., et al. SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma. Clin. Cancer Res. 21 (2015), 4184–4193.
39. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
40. Wang, J., Zhuang, J., Iyer, S., Lin, X.Y., Greven, M.C., Kim, B.H., Moore, J., Pierce, B.G., Dong, X., Virgil, D., et al. Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium. Nucleic Acids Res. 41 (2013), D171–D176.
41. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A., Weinberg, R.A., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (2004), 927–939.
42. Yang, W.H., Lan, H.Y., Huang, C.H., Tai, S.K., Tzeng, C.H., Kao, S.Y., Wu, K.J., Hung, M.C., Yang, M.H., RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 14 (2012), 366–374.
43. Youden, W.J., Index for rating diagnostic tests. Cancer 3 (1950), 32–35.
44. Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.C., LeBleu, V.S., Kalluri, R., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
45. Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W.C., Varma, S., Ballestrero, A., Doroshow, J.H., Pommier, Y., Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl. Acad. Sci. USA 109 (2012), 15030–15035.